News + Filings Transactions Holdings
All 13F 13D/G Other
|
Nestle Health Science US Holdings, Inc.
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
07/22/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
02/14/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
09/09/2020 |
SC 13G/A
| Nestle Health Science US Holdings, Inc. reports a 11.8% stake in Axcella Health Inc. |
08/19/2020 |
SC 13D/A
| Nestle Health Science US Holdings, Inc. reports a 8.8% stake in Seres Therapeutics, Inc. |
05/21/2020 |
4
| Nestle Health Science US Holdings, Inc. (10% Owner) has filed a Form 4 on Axcella Health Inc.
Txns:
| Bought 1,936,842 shares
@ $4.75, valued at
$9.2M
|
|
05/21/2020 |
SC 13G
| Nestle Health Science US Holdings, Inc. reports a 12% stake in Axcella Health Inc. |
04/24/2020 |
3
| Nestle Health Science US Holdings, Inc. (10% Owner) has filed a Form 3 on Aimmune Therapeutics, Inc. |
04/24/2020 |
4
| Nestle Health Science US Holdings, Inc. (10% Owner) has filed a Form 4 on Aimmune Therapeutics, Inc.
Txns:
| Bought 937,500 shares
@ $32, valued at
$30M
Bought 3,237,529 shares
@ $30.27, valued at
$98M
|
|
04/24/2020 |
SC 13D/A
| Nestle Health Science US Holdings, Inc. reports a 19.6% stake in Aimmune Therapeutics, Inc. |
02/14/2020 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
02/13/2020 |
SC 13G
| Nestle Health Science US Holdings, Inc. reports a 10.2% stake in Axcella Health Inc. |
02/11/2020 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
12/03/2018 |
SC 13D/A
| Nestle Health Science US Holdings, Inc. reports a 18.9% stake in Aimmune Therapeutics, Inc. |
03/02/2018 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
11/28/2016 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
11/23/2016 |
3
| Nestle Health Science US Holdings, Inc. (10% Owner) has filed a Form 3 on Aimmune Therapeutics, Inc. |
|
|